Medidata Report Reveals AI Adoption Gap in Clinical Trials
Event summary
- Medidata's 2026 AI report shows 72.9% of early adopters reducing clinical trial timelines.
- 92% of respondents plan to increase AI spending, with 82% expecting 2–3X ROI within 12-24 months.
- Top barriers to scaling AI include integration complexity (79.5%) and model accuracy (77.5%).
- Survey of 200 senior decision-makers across pharma, biotech, and CROs conducted by Everest Group.
The big picture
Medidata's findings highlight a critical inflection point in AI adoption for clinical trials, where early movers are reaping measurable benefits while others struggle with legacy infrastructure. The industry is transitioning from pilot programs to enterprise-wide integration, with data trust and regulatory compliance emerging as key differentiators. This shift underscores the growing importance of AI in accelerating drug development and improving trial outcomes, setting the stage for a new era of data-driven medicine.
What we're watching
- Adoption Gap
- How the performance gap between early AI adopters and laggards will widen as use cases mature.
- Investment Trends
- Whether the 92% increase in AI spending will translate into sustainable operational gains.
- Regulatory Compliance
- The pace at which data trust and compliance requirements will shape AI deployment strategies.
Related topics